7-demethyl-7-deoxypactamycin | 1357301-54-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-demethyl-7-deoxypactamycin
• 英文别名: Benzoic acid, 2-hydroxy-6-methyl-, [(1S,2R,3S,4S,5S)-5-[(3-acetylphenyl)amino]-4-amino-3-[[(dimethylamino)carbonyl]amino]-1,2-dihydroxy-2,3-dimethylcyclopentyl]methyl ester；[(1S,2R,3S,4S,5S)-5-(3-acetylanilino)-4-amino-3-(dimethylcarbamoylamino)-1,2-dihydroxy-2,3-dimethylcyclopentyl]methyl 2-hydroxy-6-methylbenzoate
• CAS: 1357301-54-2
• 化学式: C₂₇H₃₆N₄O₇
• 分子量: 528.605
• InChiKey: GNALXDWVGHLCBY-LUHDYUFQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  174
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  de-6MSA-7-demethyl-7-deoxypactamycin 、 在 β-ketoacyl acyl carrier synthase III like protein 、 sodium phosphate 、 magnesium chloride 作用下， 以 甘油 为溶剂， 反应 3.0h， 生成 7-demethyl-7-deoxypactamycin
  参考文献：
  名称：

  高度混杂的β-酮酰基-ACP合酶（KAS）III样蛋白参与了霉素的生物合成。

  摘要：

  β-酮酰基-酰基载体蛋白（β-酮酰基-ACP）合酶（KAS）III催化脂肪酸生物合成的第一步，涉及乙酰辅酶A起始剂单元与第一扩展剂丙二酰-ACP的克莱森缩合反应。形成乙酰乙酰基ACP。还报道了使用辅助酶A酯或离散的ACP结合底物催化类似KAS III的蛋白质催化酰基转移酶反应。在这里，我们报道了KAS III样蛋白（PtmR）的体内和体外表征，该蛋白直接将6-甲基水杨基部分从迭代I型聚酮化合物合酶转移到氨基酚戊酰胺生物合成中的氨基环戊糖醇单元中。PtmR是高度混杂的，可识别各种各样的S-酰基-N-乙酰半胱胺为底物，可生产出一系列具有多种烷基和芳香族特征的pactamycin衍生物。结果表明，KAS III样蛋白可用作修饰复杂天然产物的多功能工具。

  DOI：

  10.1021/acschembio.6b01043

文献信息

• PACTAMYCIN ANALOGS AND METHODS OF USE
  申请人：State of Oregon acting by and through the state Board of Higher Education on behalf of

  公开号：US20130231377A1

  公开（公告）日：2013-09-05

  Disclosed are pactamycin analogs, pharmaceutical compositions including the analogs, and methods of using the analogs, such as to inhibit tumor growth or a pathogenic infection such as a bacterial or parasitic infection. The pactamycin analogs have a general formula where R 1 is H, lower aliphatic, amide, acyl, or aminoacyl; R 2 is —C(O)NR 8 R 9 where R 8 and R 9 independently are hydrogen or lower aliphatic, or R 1 and R 2 together form a cyclic structure; R 3 and R 4 independently are hydrogen, hydroxyl, or lower aliphatic, or R 2 and R 3 together form a cyclic structure; R 5 is hydrogen or acyl; R 6 and R 7 independently are hydrogen, hydroxyl, halogen, lower aliphatic, or amino.
• [EN] PACTAMYCIN ANALOGS AND METHODS OF USE<br/>[FR] ANALOGUES DE LA PACTAMYCINE ET PROCÉDÉS D'UTILISATION
  申请人：OREGON STATE

  公开号：WO2012018854A2

  公开（公告）日：2012-02-09

  Disclosed are pactamycin analogs, pharmaceutical compositions including the analogs, and methods of using the analogs, such as to inhibit tumor growth or a pathogenic infection such as a bacterial or parasitic infection. The pactamycin analogs have a general formula ( I ) where R1 is H, lower aliphatic, amide, acyl, or aminoacyl; R2 is -C(0)NR8 R9 where R8 and R9 independently are hydrogen or lower aliphatic, or R1 and R2 together form a cyclic structure; R3 and R4 independently are hydrogen, hydroxyl, or lower aliphatic, or R2 and R3 together form a cyclic structure; R5 is hydrogen or acyl; R6 and R7 independently are hydrogen, hydroxyl, halogen, lower aliphatic, or amino.
• A Highly Promiscuous ß-Ketoacyl-ACP Synthase (KAS) III-like Protein Is Involved in Pactamycin Biosynthesis
  作者：Mostafa E. Abugrain、Corey J. Brumsted、Andrew R. Osborn、Benjamin Philmus、Taifo Mahmud

  DOI：10.1021/acschembio.6b01043

  日期：2017.2.17

  β-Ketoacyl–acyl carrier protein (β-Ketoacyl-ACP) synthase (KAS) III catalyzes the first step in fatty acid biosynthesis, involving a Claisen condensation of the acetyl-CoA starter unit with the first extender unit, malonyl-ACP, to form acetoacetyl-ACP. KAS III-like proteins have also been reported to catalyze acyltransferase reactions using coenzyme A esters or discrete ACP-bound substrates. Here,

  β-酮酰基-酰基载体蛋白（β-酮酰基-ACP）合酶（KAS）III催化脂肪酸生物合成的第一步，涉及乙酰辅酶A起始剂单元与第一扩展剂丙二酰-ACP的克莱森缩合反应。形成乙酰乙酰基ACP。还报道了使用辅助酶A酯或离散的ACP结合底物催化类似KAS III的蛋白质催化酰基转移酶反应。在这里，我们报道了KAS III样蛋白（PtmR）的体内和体外表征，该蛋白直接将6-甲基水杨基部分从迭代I型聚酮化合物合酶转移到氨基酚戊酰胺生物合成中的氨基环戊糖醇单元中。PtmR是高度混杂的，可识别各种各样的S-酰基-N-乙酰半胱胺为底物，可生产出一系列具有多种烷基和芳香族特征的pactamycin衍生物。结果表明，KAS III样蛋白可用作修饰复杂天然产物的多功能工具。